Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00676858
Other study ID # 2008P000124
Secondary ID
Status Completed
Phase N/A
First received May 9, 2008
Last updated March 24, 2017
Start date July 2008
Est. completion date July 5, 2011

Study information

Verified date March 2017
Source Beth Israel Deaconess Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to use transesophageal echocardiography (TEE) to determine the incidence, severity, and clinical significance of gas bubbles during argon plasma coagulation (APC).


Description:

Gas embolism is a rare but serious complication of APC. We will use TEE to monitor for gas bubbles during APC. APC will be terminated if gas bubbles are associated with ischemic heart rhythms, wall motion abnormalities, or if large gas bubbles are noted in the left ventricle.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date July 5, 2011
Est. primary completion date July 5, 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (male and female) 18 years of age or older

- Clinical indication for bronchoscopy (hemoptysis, airway obstruction, tumor excision, granulation tissue that is impairing endobronchial stent performance)

- Ability of the patient or proxy to read, comprehend, and sign informed consent document.

Exclusion Criteria:

- Presence of esophageal disorders that may complicate transesophageal echocardiography (strictures, varices, fistula, prior esophageal surgery)

- Presence of coagulopathy or other bleeding diathesis

- Inability to tolerate brief periods of apnea

- Presence of pulmonary vascular disease

- Pregnant women will not be included in this study because the potential fetal hypoxemia is not an acceptable risk.

- No exclusions will be made based on gender or race.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of gas bubbles with use of APC end of procedure
See also
  Status Clinical Trial Phase
Completed NCT03720184 - Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass N/A
Recruiting NCT00862160 - Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Phase 4